Phathom Pharmaceuticals Inc [PHAT] stock prices are up 1.36% to $11.9 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The PHAT shares have gain 8.38% over the last week, with a monthly amount drifted -0.08%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Phathom Pharmaceuticals Inc [NASDAQ: PHAT] stock has seen the most recent analyst activity on February 14, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $23. Previously, Stifel started tracking the stock with Buy rating on May 03, 2024, and set its price target to $24. On January 05, 2024, Needham reiterated its Buy rating and revised its price target to $26 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $28 on August 09, 2023. Evercore ISI upgraded its rating to a Outperform. Craig Hallum started tracking with a Buy rating for this stock on March 13, 2023, and assigned it a price target of $21. In a note dated October 21, 2022, Jefferies initiated a Buy rating and provided a target price of $16 on this stock.
The stock price of Phathom Pharmaceuticals Inc [PHAT] has been fluctuating between $2.21 and $19.50 over the past year. Currently, Wall Street analysts expect the stock to reach $23.83 within the next 12 months. Phathom Pharmaceuticals Inc [NASDAQ: PHAT] shares were valued at $11.9 at the most recent close of the market. An investor can expect a potential return of 100.25% based on the average PHAT price forecast.
Analyzing the PHAT fundamentals
The Phathom Pharmaceuticals Inc [NASDAQ:PHAT] reported sales of 114.04M for trailing twelve months, representing a surge of 439.36%. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at -2.36%, Pretax Profit Margin comes in at -2.9%, and Net Profit Margin reading is -2.9%. To continue investigating profitability, this company’s Return on Assets is posted at -1.32, Equity is 1.11 and Total Capital is -1.7. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.42.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.56 points at the first support level, and at 11.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.42, and for the 2nd resistance point, it is at 12.93.
Ratios To Look Out For
It’s worth pointing out that Phathom Pharmaceuticals Inc [NASDAQ:PHAT]’s Current Ratio is 2.38. On the other hand, the Quick Ratio is 2.35, and the Cash Ratio is 1.63. Considering the valuation of this stock, the price to sales ratio is 7.40.
Transactions by insiders
Recent insider trading involved Breedlove Robert Charles, Principal Accounting Officer, that happened on Sep 05 ’25 when 461.0 shares were sold. Principal Accounting Officer, Breedlove Robert Charles completed a deal on Jul 16 ’25 to sell 1692.0 shares. Meanwhile, Director Topper James N bought 3780.0 shares on May 21 ’25.
